Hematology

EQUATE Study Shows Early Response Rates in Severe Acute GVHD
August 11, 2020
ByHannah Slater

The study is evaluating itolizumab in patients with severe acute graft-versus-host disease as a first-line treatment concomitant with standard of care.

Phase 3 REACH3 Study Meets Primary Endpoint of Superior Overall Response Rate
July 23, 2020
ByHannah Slater

The study is evaluating ruxolitinib in patients with refractory or steroid-dependent chronic graft-versus-host disease compared to best available therapy.

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN Trial
July 16, 2020
ByConstantine Si Lun Tam, MD, MBBS, FRACP, FRCPA

The trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.